Rome, Italy | info@neomatrixbiotech.com |

News

November 21, 2024 - Neomatrix Secures EUR 1.5 Million in Funding to Advance Personalized Cancer Vaccine Development
Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies. ... (read more)

8-10 November 2024. Neomatrix presenting a Poster at SITC’s 39th Annual Meeting
the leading member-driven organization focused on cancer immunotherapy. At SITC’s Annual Meeting, international leaders from academia, regulatory and government agencies, as well as industry representatives meet for advancing Cancer Immunotherapies. ... (read more)

4-6 November 2024. Neomatrix at BioEurope in Stockholm as part of the Italian Delegation.
BIO-Europe® celebrates its 30th anniversary in Stockholm, Sweden, on November 4-6, 2024 and brings together over 5,500 delegates ... (read more)

31 October 2024. Our CEO Luigi Aurisicchio will participate as invited Speaker at The World Vaccine Congress Europe in Barcelona
Europe's largest vaccine event. Together with Big Players and other companies active in the space of personalized cancer vaccine, we will share our approach and breakthrough technology to help patients and treat cancer ... (read more)

9 October 2024. Neomatrix selected as presenting company at BioInItaly
hosted at CPHI Milan. BioInItaly brings together Corporate Venture Capitalists and Business Developers of biopharmaceuticals and biodiagnostics and, on the other, Start-ups and innovative ... (read more)

3-6 June 2024. We are attending the BIO in San Diego, California.
If you want to learn more about Neomatrix unique technology and join us in the development of next generation Cancer Vaccines ... (read more)

12 February 2024. Neomatrix was granted 258.751,70 for a Research Project on Breast Cancer.
VAP (Vaccine Ad Personam) aims to establish a new therapy based on Neomatrix technology in the context of breast cancer. In order to understand the feasibility of this innovative therapeutic approach, Neomatrix has entered into collaboration with Professor Silvia Piconese to perform molecular and immunological characterizations in the complex context of breast cancer ... (read more)

November 21, 2023. Neomatrix secures a 1 million non-dilutive grant from Lazio Innova.
4Immunogenomics aims to develop a vaccine based on synthetic DNA that incorporates liquid biopsy in the algorithm for predicting tumor targets. The main objectives of the project are two ... (read more)

June 5, 2023 - NEOMATRIX CONCLUDES SUCCESSFUL FUNDRAISING TO SUPPORT DISCOVERY AND DEVELOMENT OF PERSONALIZED CANCER VACCINES.
The biotech Neomatrix today announced that it has closed a seed funding of EUR 2 millions led by 2Invest AG and i2i Capital Limited. The funds will be used to support discovery and development of personalized cancer vaccines based on innovative DNA technology ... (read more)

May 25, 2023 - 4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA™.
Cambridge, UK , 25 May 2023 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products ... (read more)

April 8, 2021 - Neomatrix awarded at BioinItaly Investment Forum.
Neomatrix awarded at BioinItaly Investment Forum
Neomatrix was among the four start-ups awarded at the “BioinItaly Investement Forum & Intesa San Paolo start up initiative” in the Life Sciences sector, with a novel personalized approach to ... (read more)


© 2023 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED